Skip to Main content Skip to Navigation

Epissage Alternatif d'ATG16L1b : un rôle dans l'échappement des tumeurs pulmonaires aux thérapies anti-EGFR

Abstract : Identifying what is a driver oncogene and developping small molecules that are able to targetits activity led to drastic changes in NSCLC treatments. EGFR is a transmembrane receptorwith Tyrosine Kinase (TK) activity allowing signal transmission from the environment towardsthe inner of the cell by signaling pathways activation. Among those signaling pathways arefound survival and proliferation pathways. Activating mutations make EGFR a driver onco-gene, which was the first protein to be identified as such. Hence numerous chemical compoundtargeting mutated EGFR (EGFR-TKI, gefitinib) have been developped. Their use in clinicsrepresent a huge improvement for patients care. However resistance mechanisms ultimatelyoccur. Transcriptomic analyses of acquired resistant models to EGFR-TKI have shown thattheir RNA transcripts expression is abnormal. Moreover results from the team have demons-trated that SR proteins (splicing factor) expression is deregulated in NSCLC. Based on thoseresults we hypothesized that SRSF2 mediated alternative splicing of mRNA could be involvedin resistance mechanims acquired by lung carcinoma in response to EGFR-TKIThe lab developped resistant clones by chronic exposure to gefitinib of EGFR mutated lungadenocarcinoma cellular models.We first observed the accumulation of the expression of SRSF2 protein in resistant clonescompared to the sensitive cell line. Secondly, sensitivity to gefitinib induced apoptosis of twoclones was resored when neutralising SRSF2. A RNA-seq analysis led us to identify Atg16L1 aspotentially being involved in the SRSF2-mediated sensitization to gefitinib-induced apoptosis.SRSF2 neutralisation modulates Atg16L1 splicing in response to gefitinib. Neutralisation ofExon 8 containing transcripts of Atg16L1 sensitizes resistant clones to gefitinib induced apop-tosis. This alternative splicing switch modulates autophagic activity of the cells in reponseto gefitinib. We have shown that exon8 containing transcripts favor autophagy inhibition inreponse to gefitinib. This work emphasize the role of Atg16L1 alternative splicing switch ofexon8 in autophagy inhibition and its correlation with a resistant phenotype in response toEGFR-TKI. SRSF2 may participate in the modulation of this alternative splicing switch inreponse to gefitinib.
Document type :
Complete list of metadatas

Cited literature [461 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Monday, September 2, 2019 - 1:10:08 AM
Last modification on : Friday, November 20, 2020 - 1:00:06 PM
Long-term archiving on: : Thursday, January 9, 2020 - 3:03:48 AM


Version validated by the jury (STAR)


  • HAL Id : tel-02275789, version 1




Anne-Sophie Hatat. Epissage Alternatif d'ATG16L1b : un rôle dans l'échappement des tumeurs pulmonaires aux thérapies anti-EGFR. Cancer. Université Grenoble Alpes, 2018. Français. ⟨NNT : 2018GREAV027⟩. ⟨tel-02275789⟩



Record views


Files downloads